Julie Milia

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

J. Mazieres, Alexander Drilon, Amélie Lusque et al. · Annals of Oncology · 2019 · 1.3K citations · Full text

Advanced Lung Cancer, Cancer Immunosurveillance, Medicine +12

Lung Cancer That Harbors an <i>HER2</i> Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

Julien Mazières, Solange Peters, Benoît Lepage et al. · Journal of Clinical Oncology · 2013 · 651 citations

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

Myriam Delaunay, J. Cadranel, Amélie Lusque et al. · European Respiratory Journal · 2017 · 416 citations · Full text

Targeting RET in Patients With <i>RET</i>-Rearranged Lung Cancers: Results From the Global, Multicenter <i>RET</i> Registry

Oliver Gautschi, Julie Milia, Thomas Filleron et al. · Journal of Clinical Oncology · 2017 · 349 citations · Full text

Crizotinib Therapy for Advanced Lung Adenocarcinoma and a <i>ROS1</i> Rearrangement: Results From the EUROS1 Cohort

Julien Mazières, Gérard Zalcman, Lucio Crinò et al. · Journal of Clinical Oncology · 2015 · 348 citations · Full text